Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Where Global Blood Therapeutics Stands With Analysts
12:16pm, Tuesday, 09'th Aug 2022 Benzinga
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
7
Pfizer is acquiring Global Blood Therapeutics
11:49am, Tuesday, 09'th Aug 2022
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the de
Pfizer to buy Global Blood Therapeutics for US$5.4bn
06:18am, Tuesday, 09'th Aug 2022
Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
06:51pm, Monday, 08'th Aug 2022 The Motley Fool
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
06:50pm, Monday, 08'th Aug 2022 Benzinga
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).
Pfizer said i
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
03:18pm, Monday, 08'th Aug 2022
NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Globa
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
02:51pm, Monday, 08'th Aug 2022
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
02:10pm, Monday, 08'th Aug 2022 Benzinga
Upgrades
For iRobot Corp (NASDAQ:IRBT), JP Morgan upgraded the previous rating of Underweight to Neutral. In the second quarter, iRobot showed an EPS of $0.35, compared to $0.27 from the year-ago qua
Biotech Wins Last Week: 5 Best ETFs
02:05pm, Monday, 08'th Aug 2022 Zacks Investment Research
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
12:12pm, Monday, 08'th Aug 2022
Source: ra2 studio/Shutterstock Last week, Global Blood Therapeutics (NASDAQ: GBT ) stock was thrust into the spotlight on reports of a potential buyout bid from Pfizer (NYSE: PFE ). Today, though, Pf
Veteran strategist Dennis Gartman says it's still a bear market with no Fed pivot in sight.
11:07am, Monday, 08'th Aug 2022 MarketWatch
Gartman said he likes stocks in motion as the long-time Wall Street veteran says it's still a bear market for equities.
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
10:45am, Monday, 08'th Aug 2022 GlobeNewswire Inc.
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
09:13am, Monday, 08'th Aug 2022 Benzinga
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Carvana Co. (NYSE: CVNA) jumped 40.1% to clo
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
09:05am, Monday, 08'th Aug 2022
Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week. The post Pfizer Inks $5.4 Billion Deal To Acquire Global Blood T
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
09:01am, Monday, 08'th Aug 2022
Pfizer said it would pay $68.50 per share for Global Blood Therapeutics which sells a sickle cell disease treatment called Oxbryta
